Introduction
Quinupristin/dalfopristin is an investigational parenteral streptogramin antibiotic that consists of a 30 : 70 mixture of quinupristin and dalfopristin. 1 The combination acts synergically by binding to two separate sites on the bacterial 50S ribosome and affords activity against many Gram-positive bacterial species that demonstrate macrolide-lincosamide-streptogramin (MLS) type resistance. [2] [3] [4] Quinupristin/dalfopristin has a unique spectrum of antibacterial activity that includes Gram-negative cocci and most Gram-positive bacteria. 4, 5 Appreciable activity has also been demonstrated against Haemophilus influenzae, although media and testing differences have contributed to an inconclusive view of the possible role of quinupristin/dalfopristin in the therapy of H. influenzae infections. [4] [5] [6] This study has evaluated the in-vitro activity of quinupristin/dalfopristin against H. influenzae isolates, including strains resistant to antimicrobial agents of various drug classes. Two different broth media, an agar dilution test format, and different quinupristin/dalfopristin combinations were employed in an effort to determine the optimal test method.
Materials and methods

Test strains
A group of 100 well-characterized H. influenzae strains isolated from clinical sources over several years was used in this study. They included strains of normal susceptibility and strains with resistance to several different antimicrobial agents, including ampicillin (due to -lactamase and non-enzymatic mechanisms), chloramphenicol, tetracycline, trimethoprim-sulphamethoxazole and rifampicin. Both serotype b and unencapsulated strains were included. 
Broth microdilution susceptibility tests
Broth microdilution MIC tests were performed with Haemophilus test medium (HTM) as presently advocated by the National Committee for Clinical Laboratory Standards (NCCLS) 7 and also with the medium previously recommended by the NCCLS, namely, cationadjusted Mueller-Hinton broth supplemented with 3% lysed horse blood and 10 mg/L NAD.
8 A final inoculum of 5 10 5 cfu/mL and incubation for 20-24 h at 35°C in ambient air were employed with both media.
Agar dilution susceptibility tests
Agar dilution MIC tests were performed with HTM agar, a final inoculum of 1 10 4 cfu/spot, and incubation for 20-24 h at 35°C. 9 Agar dilution tests with quinupristin/ dalfopristin, quinupristin, dalfopristin, ampicillin and erythromycin were performed in duplicate with one set of plates incubated in a 5% CO 2 environment and the other incubated in ambient air for 20-24 h at 35°C.
Results
The MICs of quinupristin/dalfopristin, its two components, and seven other antimicrobial agents as determined by the NCCLS reference broth microdilution method are shown in Table I . MICs of quinupristin/dalfopristin and dalfopristin were essentially the same, and were much lower than the MICs for quinupristin. The strain collection included isolates resistant to ampicillin, cefuroxime, chloramphenicol, rifampicin, tetracycline and trimethoprim-sulphamethoxazole, as well as isolates hypersusceptible or resistant to erythromycin. While resistance to the above agents did not affect susceptibility to quinupristin/ dalfopristin or its components, the quinupristin/ dalfopristin and dalfopristin MICs closely paralleled the erythromycin MICs. Thus, strains that were highly susceptible to erythromycin were also very susceptible to the combination and to dalfopristin, the component that is more active against H. influenzae.
MICs of quinupristin/dalfopristin, its components, and ampicillin and erythromycin, determined with two different broth dilution media and by agar dilution testing in ambient air or CO 2 incubation, are shown in Table II . Compared with the results obtained using NCCLS-HTM broth dilution, the MICs of quinupristin/dalfopristin and its component were the same or one dilution higher when determined in lysed horse blood broth or HTM agar dilution tests incubated in air. MICs determined by HTM agar dilution incubated in a CO 2 atmosphere were equivalent or at most one dilution lower than MICs determined by the NCCLS reference broth procedure. Table III shows the MIC 50 and MIC 90 quinupristin/dalfopristin, its two components, and erythromycin and ampicillin with the different test media and incubation conditions. 
Discussion
Quinupristin/dalfopristin is a new parenteral streptogramin with promising activity against many Gram-positive bacteria, including some highly resistant organisms such as methicillin-resistant staphylococci, vancomycinresistant Enterococcus faecium, and multiply resistant S. pneumoniae. 5, 10, 11 While quinupristin/dalfopristin is active against some fastidious Gram-negative species (e.g. Moraxella catarrhalis, Neisseria spp.), it is less active against H. influenzae. The explanation for the modest activity of quinupristin/dalfopristin against H. influenzae may be a failure of the two components to provide the magnitude of synergic effect noted with many Gram-positive species. 1, 2, 4 Our results indicate that the majority of the activity of quinupristin/dalfopristin against H. influenzae is due to the dalfopristin component. Indeed, with many strains, the dalfopristin and quinupristin/dalfopristin MICs were identical. This could be due to lower penetration of quinupristin into haemophilus cells or perhaps to less efficient binding of quinupristin to the bacterial ribosome. Altering the ratios of the quinupristin/dalfopristin components between 1:9 and 9:1 did not enhance the activity against a subset of 20 of the test strains.
Strains of haemophilus that were highly susceptible to erythromycin were also highly susceptible to quinupristin/dalfopristin and its components, and vice versa. In this study we used strains with elevated macrolide MICs, thus resulting in quinupristin/dalfopristin MIC 50 and MIC 90 values somewhat higher than those reported in some previous studies, 4, 6 but similar to the findings of Barry & Fuchs. 5 Because of the unique mechanism of antimicrobial action of streptogramins, resistance mechanisms affecting -lactams, chloramphenicol, rifampicin, tetracycline or trimethoprim-sulphamethoxazole did not affect susceptibility of the haemophilus test strains to quinupristin/dalfopristin.
The dilution method (broth or agar) and the type of medium used for susceptibility testing did not significantly affect the MICs of quinupristin/dalfopristin or its components against H. influenzae in this study (Table III) . While slight differences in MICs were noted between testing methods, the differences were no greater than with the two comparator drugs, erythromycin and ampicillin. Thus, the NCCLS reference broth microdilution procedure incorporating HTM broth appears to be an acceptable method for assessing the susceptibility of H. influenzae isolates to quinupristin/dalfopristin. The activity of quinupristin/dalfopristin against H. influenzae appears to be less than its activity against many Gram-positive bacterial pathogens and some other Gramnegative pathogens, e.g. M. catarrhalis. If H. influenzae were effectively inhibited by quinupristin/dalfopristin, it might be suitable for empirical therapy of serious community-acquired respiratory infections that could also be caused by Gram-positive bacteria (i.e. staphylococci and streptococci). It will be important to determine respiratory mucosal surface concentrations of quinupristin/dalfopristin, as well as its in-vivo effectiveness in animal models of infection or in human respiratory infections, in order to evaluate its ultimate utility against H. influenzae. 
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